

Attorney Docket No.: 6594.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Sauerberg et al.

Serial No.: 10/734,368

Group Art Unit: To be assigned

Filed: December 12, 2003

Examiner: To be assigned

For: Novel Compounds, Their Preparation and Use

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References (24)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on **February 16, 2004**

Dolly Kapadia  
(name of person mailing paper)

*Dolly Kapadia*  
(signature of person mailing paper)



Attorney Docket No.: 6594.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Sauerberg et al.

Application No.: 10/734,368

Group Art Unit: To be assigned

Filed: December 12, 2003

Examiner: To be assigned

For: Novel Compounds, Their Preparation and Use

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. U.S. Patent No. 5,063,240
2. U.S. Patent No. 5,306,726
3. WO 91/19702 A1
4. WO 94/01420 A1

5. WO 94/13650 A1
6. WO 94/25448 A1
7. WO 95/03038 A1
8. WO 95/17394 A1
9. WO 96/04260 A1
10. WO 97/25042 A1
11. WO 97/36579 A1
12. WO 99/08501 A2
13. WO 99/16758 A1
14. WO 99/19313 A1
15. WO 99/63983 A1
16. WO 01/00603 A1
17. EP 0597102 A1
18. EP 0696585 B1
19. JP 08/217766 – Translation
20. JP 09/291031 – Translation
21. Berger et al., The Journal of Biological Chemistry, Vol. 274, No. 10, pages 6718-6725 (1999)
22. Leibowitz et al., FEBS Letters 473, pages 333-336 (2000)
23. Muoio et al., The Journal of Biological Chemistry, Vol. 277, No. 29, pages 26089-26097 (2002)
24. Oliver et al., PNAS, Vol. 98, No. 9, pages 5306-5311 (2001)


It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office

action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Date: February 16, 2004

Respectfully submitted,




Rosemarie R. Wilk-Orescan, Reg. No. 45,220  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800

**Use the following customer number for all correspondence regarding this application.**

**23650**

PATENT TRADEMARK OFFICE

FORM PTO-1449  
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6594.200-US

Serial No. 10/734,368

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Applicant Sauerberg et al.

(Use several sheets if necessary)

Filing Date December 12, 2003

Group To be assigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,063,240	11/5/91	Hindley	514	369	
	5,306,726	4/26/94	Hulin	514	375	

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 91/19702 A1	12/26/91	PCT				
	WO 94/01420 A1	1/20/94	PCT				
	WO 94/13650 A1	6/23/94	PCT				
	WO 94/25448 A1	11/10/94	PCT				
	WO 95/03038 A1	2/2/95	PCT				
	WO 95/17394 A1	6/29/95	PCT				
	WO 96/04260 A1	2/15/96	PCT				
	WO 97/25042 A1	7/17/97	PCT				
	WO 97/36579 A1	10/9/97	PCT				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Berger et al., The Journal of Biological Chemistry, Vol. 274, No. 10, pages 6718-6725 (1999)
	Leibowitz et al., FEBS Letters 473, pages 333-336 (2000)
	Muoio et al., The Journal of Biological Chemistry, Vol. 277, No. 29, pages 26089-26097 (2002)
	Oliver et al., PNAS, Vol. 98, No. 9, pages 5306-5311 (2001)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449  
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6594.200-US

Serial No. 10/734,368

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Applicant Sauerberg et al.

(Use several sheets if necessary)

Filing Date December 12, 2003

Group To be assigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 99/08501 A2	2/25/99	PCT				
	WO 99/16758 A1	4/8/99	PCT				
	WO 99/19313 A1	4/22/99	PCT				
	WO 99/63983 A1	12/16/99	PCT				
	WO 01/00603 A1	1/4/01	PCT				
	EP 0597102 A1	5/18/94	EPO				
	EP 0696585 B1	2/14/96	EPO				
	JP 08/217766	8/27/96	JP				
	JP 09/291031	11/11/97	JP				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.